KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biogen (BIIB) EBT (2016 - 2026)

Biogen has reported EBT over the past 18 years, most recently at $377.7 million for Q1 2026.

  • For Q1 2026, EBT rose 21.37% year-over-year to $377.7 million; the TTM value through Mar 2026 reached $1.6 billion, down 7.38%, while the annual FY2025 figure was $1.6 billion, 18.34% down from the prior year.
  • EBT for Q1 2026 was $377.7 million at Biogen, up from -$56.0 million in the prior quarter.
  • Over five years, EBT peaked at $1.4 billion in Q3 2022 and troughed at -$141.2 million in Q3 2023.
  • A 5-year average of $513.5 million and a median of $451.0 million in 2024 define the central range for EBT.
  • Biggest five-year swings in EBT: skyrocketed 419.41% in 2024 and later crashed 119.21% in 2025.
  • Year by year, EBT stood at $603.8 million in 2022, then crashed by 51.71% to $291.6 million in 2023, then fell by 0.03% to $291.5 million in 2024, then crashed by 119.21% to -$56.0 million in 2025, then surged by 774.46% to $377.7 million in 2026.
  • Business Quant data shows EBT for BIIB at $377.7 million in Q1 2026, -$56.0 million in Q4 2025, and $557.3 million in Q3 2025.